600594 益佰制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.538-11.8053.599-14.1407.472
总资产报酬率 ROA (%)-2.181-7.2952.227-9.1374.899
投入资产回报率 ROIC (%)-2.478-8.3382.563-10.4745.532

边际利润分析
销售毛利率 (%)60.32361.84869.47170.96378.754
营业利润率 (%)-6.215-14.3634.870-13.7459.424
息税前利润/营业总收入 (%)-5.326-14.3865.245-13.11610.182
净利润/营业总收入 (%)-6.265-15.3943.239-16.4426.896

收益指标分析
经营活动净收益/利润总额(%)65.61778.423150.494-53.505144.023
价值变动净收益/利润总额(%)0.388-0.1020.0220.04211.161
营业外收支净额/利润总额(%)3.3326.095-3.8074.107-1.624

偿债能力分析
流动比率 (X)1.8771.8442.2261.7401.593
速动比率 (X)1.2491.2041.5951.2071.080
资产负债率 (%)34.46236.43234.34735.83930.754
带息债务/全部投入资本 (%)22.79123.89221.84125.13720.305
股东权益/带息债务 (%)309.808290.853328.028281.679379.863
股东权益/负债合计 (%)181.684166.696182.676170.342221.220
利息保障倍数 (X)-4.825-15.8319.479-10.76911.209

营运能力分析
应收账款周转天数 (天)34.10734.64333.28641.81435.376
存货周转天数 (天)271.233259.207253.296267.364266.560